The empowerment of translational research: lessons from laminopathies by Benedetti, S et al.
Benedetti et al. Orphanet Journal of Rare Diseases 2012, 7:37
http://www.ojrd.com/content/7/1/37LETTER TO THE EDITOR Open AccessThe empowerment of translational research:
lessons from laminopathies
Sara Benedetti1, Pia Bernasconi2, Enrico Bertini3, Elena Biagini4, Giuseppe Boriani4, Cristina Capanni5,
Nicola Carboni6, Giovanna Cenacchi7, Marta Columbaro8, Monica D'Adamo9, Adele D’Amico3,
Maria Rosaria D’Apice10, Marianna Fontana11, Alessandra Gambineri12, Giovanna Lattanzi5*, Rocco Liguori13,
Nadir M Maraldi8, Laura Mazzanti14, Eugenio Mercuri15, Tiziana Mongini16, Lucia O Morandi2, Iria Neri17,
Giovanni Nigro18, Giuseppe Novelli19, Michela Ortolani5, Renato Pasquali12, Antonella Pini20, Stefania Petrini3,
Luisa Politano18, Stefano Previtali21, Lisa Pucci22, Claudio Rapezzi4, Giulia Ricci23, Carmelo Rodolico24,
Paolo Sbraccia9, Emanuela Scarano14, Gabriele Siciliano23, Stefano Squarzoni5, Antonio Toscano24,
Liliana Vercelli16 and Matteo Ziacchi4Abstract
The need for a collaborative approach to complex inherited diseases collectively referred to as laminopathies,
encouraged Italian researchers, geneticists, physicians and patients to join in the Italian Network for Laminopathies,
in 2009. Here, we highlight the advantages and added value of such a multidisciplinary effort to understand
pathogenesis, clinical aspects and try to find a cure for Emery-Dreifuss muscular dystrophy, Mandibuloacral
dysplasia, Hutchinson-Gilford Progeria and forms of lamin-linked cardiomyopathy, neuropathy and lipodystrophy.
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Empowerment is the process of increasing the capacity
of individuals or groups to make choices and to trans-
form those choices into desired actions and outcomes.
Empowerment is a necessity for patients with rare dis-
eases, which are chronic, difficult to manage, so rare that
coordinated efforts are imperative to make progress, and
largely disregarded by the research or medical commu-
nity and policy makers.
Individual empowerment is a reality for patients with
rare diseases, which has been mediated by the rapid
growth of web-based health-related information. Thus, a
patients need of knowledge and support leads to the
need for associations, which are able to collect and
analyze the data of individual cases and present the* Correspondence: lattanzi@area.bo.cnr.it
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reproduction in any medium, provided the orlessons learned from each case in the context of the dis-
ease as a whole. The need for networking comes from
the above-mentioned situation, yet, in the case of lami-
nopathies, the need comes also from the nature and
complexity of diseases.
The story of laminopathies began with the discovery,
in 1994, that the Emery-Dreifuss muscular dystrophy
was caused by mutations in EMD gene encoding a pro-
tein of the nuclear envelope [1]. During the following
ten years, more than twelve diseases have been linked to
mutations in lamin A/C [2], a main component of the
nuclear lamina. Along with the lamin proteins other nu-
clear envelope proteins have also been associated with
rare inherited disorders. All these diseases are currently
refereed to as laminopathies. They include Emery-
Dreifuss muscular dystrophy, limb-girdle muscular dys-
trophy type 1B, dilated cardiomyopathy with conduction
defects, Dunnigan type familial partial lipodystrophy,
Mandibuloacral dysplasia [3] and Hutchinson-Gilford
progeria syndrome, atypical-Werner syndrome, Heart-ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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2B1, restrictive dermopathy, autosomal dominant leuco-
dystrophy, osteopoikilosis and other partially overlapping
diseases [4].
Each laminopathy presents with typical clinical fea-
tures, yet several aspects are shared by muscle and adi-
pose tissue laminopathies or by premature ageing
diseases and lipodystrophies. Thus, an interdisciplinary
clinical approach is expected to yield better diagnosis,
better follow-up and therapeutic chances. In fact, the
most relevant advances in understanding the pathogen-
esis of lamin-linked diseases and of lamin function have
been obtained after the discovery of syndromic lamino-
pathies. The study of syndromic laminopathies, based on
their molecular, cellular and clinical aspects, suggested
major pathogenetic pathways to be explored in tissue-
specific laminopathies. Moreover, given that most lami-
nopathies affect tissues of mesenchimal origin and likely
involve altered mesenchimal stem cell commitment or
differentiation, pathogenetic mechanisms likely overlap
and require a comprehensive view in order to unravel
the role of lamin. These considerations provide evidence
of the extent to which an Italian Network for Laminopa-
thies, involving centers spread throughout Italy and
involved in clinics, research, industry and patients and
their associations can help in addressing the study of
those diseases and finding a therapeutic strategy. As in
any rare disease, the information is not well known
among family doctors and even in specialized centers. In
this context, a major aim of the Network is to expand
knowledge and increase interest in diagnostic protocols
and detection of symptoms.
Two main features of the Network make it efficient in
reaching the objectives of an interdisciplinary approach
to diagnosis, therapy and research activity. First, meet-
ings of all Network partners are regularly held twice a
year and researchers, clinicians and patients participate
with data presentations, sharing of clinical aspects and
suggesting new initiatives. Secondly, the Network web-
site (http://www.igm.cnr.it/laminopatie/) is a platform to
share scientific news, information about the diseases,
available treatments and the location of knowledgeable
clinicians. Successful completion of this information is
the result of collaborations involving patients, physi-
cians, other health-care providers and researchers.
A major result of the Network’s activity was the first
Italian meeting course on Laminopathies, held in Bol-
ogna on April 2011 [5]. The meeting gave patients, fam-
ily doctors and specialists in several disciplines the
opportunity to be brought up-to-date on the most recent
advances in the field of laminopathy diagnosis, clinical
follow-up and research.
Finally, Network partners are developing collabora-
tions in scientific and clinical projects. A critical mass ofprofessionals, patients and biological samples gives un-
expected opportunities to design comprehensive studies
and search for biomarkers of disease, drug targets and
pharmacological tools.
We propose that similar initiatives may be extended to
other countries, involving people involved to different
degrees in various aspects of laminopathies, to bring a
multidisciplinary contribution to the understanding of
diseases. Such an approach might prove useful for simi-
lar situations, especially when diverse clinical entities are
associated with overlapping genetic and clinical tracts.
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